{
    "clinical_study": {
        "@rank": "21672", 
        "arm_group": {
            "arm_group_label": "OCA: 10 mg", 
            "arm_group_type": "Experimental", 
            "description": "obeticholic acid, oral administration, 10mg, 8 weeks"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if obeticholic acid (OCA) has an effect on\n      cholesterol levels in the blood in patients with PBC."
        }, 
        "brief_title": "Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Primary Biliary Cirrhosis", 
        "condition_browse": {
            "mesh_term": [
                "Liver Cirrhosis, Biliary", 
                "Liver Cirrhosis", 
                "Fibrosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Definite or probable primary biliary cirrhosis (PBC) diagnosis as demonstrated by the\n             presence of \u2265 2 of the following 3 diagnostic factors:\n\n               -  History of elevated alkaline phosphatase (ALP) levels for at least 6 months\n\n               -  A positive anti-microbial antibody (AMA) titer or, if AMA negative or in low\n                  titer (<1:80), PBC specific antibodies\n\n               -  Liver biopsy consistent with PBC\n\n          2. Age \u2265 18 years\n\n          3. Taking UDCA for at least 12 months (stable dose for \u2265 3 months) prior to Day 0 or\n             unable to tolerate UDCA (no UDCA for \u2265 3 months prior to Day 0)\n\n          4. Contraception:  Female subjects must be postmenopausal, surgically sterile, or if\n             premenopausal, be prepared to use \u2265 1 effective (\u2264 1% failure rate) method of\n             contraception during the trial and until at least 30 days after the last dose of\n             Investigational Product.\n\n          5. Must provide written informed consent and agree to comply with the trial protocol.\n\n        Exclusion Criteria:\n\n          1. Subjects with decompensated PBC (as determined by the Investigator)\n\n          2. Severe pruritus or systemic treatment for pruritus (e.g. treatment with bile acid\n             sequestrants or rifampicin) within 2 months of Day 0\n\n          3. History or presence of other significant liver diseases including:\n\n               -  Active or chronic Hepatitis B or C virus (HBV, HCV) infection\n\n               -  Primary sclerosing cholangitis (PSC)\n\n               -  Alcoholic liver disease\n\n               -  Definite autoimmune liver disease or overlap hepatitis\n\n               -  Nonalcoholic steatohepatitis (NASH)\n\n             NOTE: Subjects with Gilbert's disease or those with a history of hepatitis B who are\n             currently antigen negative and seroconverted should not be considered exclusionary\n\n          4. Uncontrolled diabetes or other uncontrolled or unstable medical condition that may\n             interfere with trial results\n\n          5. Administration of any of the following medications as specified below:\n\n               -  Prohibited 28 days prior to Day 0: bile acid sequestrants (BAS) including\n                  cholestyramine, colesevelam, or colestipol\n\n               -  Prohibited 3 months prior to Day 0 and throughout trial participation:\n                  serum-lipid modifying agents including 3-hydroxy-3-methylglutaryl-coenzyme A\n                  (HMG CoA) reductase inhibitors, fenofibrate or other fibrates, nicotinic acid\n                  and derivatives, ezetimibe, Vitamin E (other than as standard dietary\n                  supplement), omega-3 fatty acid containing dietary supplements\n\n               -  Prohibited 6 months prior to Day 0 and throughout the trial participation:\n                  azathioprine, colchicine, cyclosporine, methotrexate, mycophenolate mofetil,\n                  pentoxifylline; budesonide and other systemic corticosteroids; potentially\n                  hepatotoxic drugs (including \u03b1-methyl-dopa, sodium valproic acid, isoniazide, or\n                  nitrofurantoin)\n\n               -  Prohibited 12 months prior to Day 0 and throughout the trial participation:\n                  antibodies or immunotherapy directed against interleukins or other cytokines or\n                  chemokines\n\n          6. Planned change in diet or exercise habits during participation in the trial\n\n          7. Presence or history of clinically significant cardiac arrhythmias that may prohibit\n             the subject from participating in the trial\n\n          8. If female: known pregnancy, or has a positive urine pregnancy test (confirmed by a\n             positive serum pregnancy test), or lactating\n\n          9. Recent (3 months prior to day 0) participation in another trial involving OCA or\n             participation in another investigational trial (30 days prior to Day 0) and during\n             the trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01865812", 
            "org_study_id": "747-205"
        }, 
        "intervention": {
            "arm_group_label": "OCA: 10 mg", 
            "description": "All subjects will be treated with OCA (oral administration, 10 mg, once daily) for 8 weeks and should continue their prestudy dose of ursodeoxycholic acid (UDCA).", 
            "intervention_name": "obeticholic acid (OCA)", 
            "intervention_type": "Drug", 
            "other_name": "6\u03b1-ethyl chenodeoxycholic acid (6-ECDCA); INT-747"
        }, 
        "intervention_browse": {
            "mesh_term": "Chenodeoxycholic Acid"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "December 12, 2013", 
        "location": [
            {
                "contact": {
                    "email": "scarvalho@med.miami.edu", 
                    "last_name": "Sonia Carvalho", 
                    "phone": "305-243-4639"
                }, 
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33136"
                    }, 
                    "name": "University of Miami"
                }, 
                "investigator": {
                    "last_name": "Cynthia Levy, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "keach.jill@mayo.edu", 
                    "last_name": "Jill Keach", 
                    "phone": "507-538-0678"
                }, 
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55905"
                    }, 
                    "name": "Mayo Clinic"
                }, 
                "investigator": {
                    "last_name": "Jayant Talwalkar, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "dukim@chpnet.org", 
                    "last_name": "Duyang Kim, MPH", 
                    "phone": "212-844-6446"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10003"
                    }, 
                    "name": "Beth Israel Medical Center"
                }, 
                "investigator": {
                    "last_name": "Henry C. Bodenheimer, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kimberly.williams1@va.gov", 
                    "last_name": "Kimberly Williams", 
                    "phone": "804-675-6848"
                }, 
                "facility": {
                    "address": {
                        "city": "Richmond", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23249"
                    }, 
                    "name": "McGuire DVAMC"
                }, 
                "investigator": {
                    "last_name": "Velimir A. Luketic, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "anhaita.jamula@vmmc.org", 
                    "last_name": "Anhaita Jamula", 
                    "phone": "206-341-1978"
                }, 
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98034"
                    }, 
                    "name": "Virginia Mason Medical Center"
                }, 
                "investigator": {
                    "last_name": "Kris Kowdley, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2 Clinical Trial Investigating the Effects of Obeticholic Acid on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis", 
        "other_outcome": [
            {
                "measure": "Fasting levels of OCA and Conjugates", 
                "safety_issue": "No", 
                "time_frame": "Week 8"
            }, 
            {
                "measure": "Change from baseline in fibroblast growth factor 19 (FGF-19)", 
                "safety_issue": "No", 
                "time_frame": "Week 4, Week 8 and Week 12"
            }, 
            {
                "measure": "Change from baseline in Lipoprotein X", 
                "safety_issue": "No", 
                "time_frame": "Week 4, Week 8 and Week 12"
            }, 
            {
                "measure": "Markers of inflammation including: C-Reactive Protein, GlycA and GlycB", 
                "safety_issue": "No", 
                "time_frame": "Week 8"
            }
        ], 
        "overall_contact": {
            "email": "csciacca@interceptpharma.com", 
            "last_name": "Cathi I. Sciacca", 
            "phone": "858-652-6803"
        }, 
        "overall_contact_backup": {
            "email": "kfowler@interceptpharma.com", 
            "last_name": "Kimberly Fowler", 
            "phone": "858-964-1573"
        }, 
        "overall_official": {
            "affiliation": "Intercept Pharmaceuticals", 
            "last_name": "David Shapiro, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "HDL metabolism will be assessed by measuring HDL cholesterol concentration, HDL particle size and number.", 
            "measure": "Change from baseline in High-density lipoprotein (HDL) Metabolism", 
            "safety_issue": "No", 
            "time_frame": "Week 4, Week 8 and Week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01865812"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Lipoprotein metabolism will be assessed by measuring the following:\nconcentrations of total cholesterol and triglycerides\nLow-density lipoprotein (LDL) and very low density lipoprotein (VLDL) cholesterol concentrations, particle size and number\nconcentrations of apolipoprotein A (ApoA), apolipoprotein B (ApoB), apolipoprotein E (ApoE), and lipoprotein (a) [Lp(a)]", 
                "measure": "Change from baseline in Lipoprotein Metabolism", 
                "safety_issue": "No", 
                "time_frame": "Week 4, Week 8 and Week 12"
            }, 
            {
                "description": "Components of reverse cholesterol transport will also be assessed as part of the lipoprotein analysis. This will include measurements of:\nHDL capacity to accept cholesterol measured by lecithin-cholesterol acyltransferase (LCAT) and Cholesterol ester transfer protein (CETP) activity.\npre-\u03b21 HDL concentration\nmacrophage cholesterol efflux", 
                "measure": "Change from baseline Reverse Cholesterol Transport", 
                "safety_issue": "No", 
                "time_frame": "Week 4, Week 8 and Week 12"
            }, 
            {
                "description": "In a subset of patients who agree to participate, non-compartmental pharmacokinetic parameters of OCA and its conjugates (glyco-OCA and tauro-OCA) will be assessed.", 
                "measure": "Pharmacokinetic parameters of OCA and OCA conjugates", 
                "safety_issue": "No", 
                "time_frame": "Week 8"
            }
        ], 
        "source": "Intercept Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Intercept Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}